Axa S.A. Trims Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

AXA S.A. cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 44.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 186,813 shares of the medical equipment provider's stock after selling 149,206 shares during the quarter. AXA S.A. owned about 0.08% of Hologic worth $13,467,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HOLX. Barclays PLC boosted its holdings in Hologic by 47.6% during the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock valued at $58,507,000 after acquiring an additional 231,578 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Hologic during the 3rd quarter valued at about $93,000. Tidal Investments LLC boosted its holdings in Hologic by 60.1% during the 3rd quarter. Tidal Investments LLC now owns 15,351 shares of the medical equipment provider's stock valued at $1,250,000 after acquiring an additional 5,764 shares during the period. Franklin Resources Inc. boosted its holdings in Hologic by 171.7% during the 3rd quarter. Franklin Resources Inc. now owns 278,295 shares of the medical equipment provider's stock valued at $22,714,000 after acquiring an additional 175,855 shares during the period. Finally, Principal Financial Group Inc. raised its position in Hologic by 3.6% in the 3rd quarter. Principal Financial Group Inc. now owns 269,546 shares of the medical equipment provider's stock valued at $21,957,000 after purchasing an additional 9,419 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Price Performance

HOLX stock traded up $0.56 on Friday, reaching $56.74. 3,258,934 shares of the company's stock were exchanged, compared to its average volume of 2,092,764. The stock has a fifty day moving average of $59.43 and a 200-day moving average of $68.17. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.67. The firm has a market cap of $12.73 billion, a PE ratio of 17.90, a P/E/G ratio of 2.14 and a beta of 0.54. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same quarter in the prior year, the company posted $1.03 earnings per share. Hologic's quarterly revenue was down 1.2% on a year-over-year basis. As a group, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on HOLX. Argus lowered Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. William Blair reaffirmed an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Raymond James reaffirmed an "outperform" rating and issued a $71.00 price target (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Leerink Partnrs lowered Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Finally, Stephens reissued an "overweight" rating and set a $84.00 target price on shares of Hologic in a research report on Thursday, February 6th. Twelve research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Hologic has a consensus rating of "Hold" and a consensus price target of $78.58.

Insider Buying and Selling

In other news, Director Martin D. Madaus bought 5,445 shares of the stock in a transaction on Wednesday, May 7th. The shares were bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.88% of the stock is currently owned by corporate insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.